Abstract:Inequalities in the provision of psychological therapies for schizophrenia persist. Good quality cognitive behavioural therapy and FI training do not ensure implementation. Collaboration at all levels of healthcare is needed for effective implementation.
“…Such barriers are not about the lack of knowledge, but the lack of use of existing knowledge, given that practice guidelines (eg, cognitive behavioral therapy for psychosis, and family interventions) are rarely offered systematically in clinical practice. 12,13 Difficulties include the transfer of knowledge gained under rigorous experimental conditions to clinical settings, which are often under-resourced and under pressure to provide services to clients with varied capacity and multiple comorbidities. Discussions considered the value of stepped-care models for hallucinations that provide low-intensity, low-cost, and highly accessible treatments, suitable for use by different practitioners and enhanced collaborative efforts amongst "voices clinics" to develop, test, and make widely available educational materials and resources for use across internationally varied mental health service systems.…”
a public conference in which research findings were considered in relation to subjective experience and practice, 9 multidisciplinary working groups examined key current issues in progressing the conceptualization and research of hallucinations. Work group topics included: multicenter validation of the transdiagnostic and multimodal Questionnaire for Psychotic Experiences; development of an improved outcome measure for psychological therapies; the relationship between inhibition and hallucinations across multiple levels of explanation; hallucinations in relation to sleep phenomena; emotion and hallucinations; multiple interactions between the experience of self and hallucinations; interactions between language, auditory and memory networks; resting state networks including the default mode; and analyses arising from functional magnetic resonance imaging (fMRI) data-sharing. Major themes in hallucinations research identified during the meeting included (1) progression beyond the auditory verbal modality in schizophrenia to consider hallucinations across modalities and different populations; (2) development of new measures; (3) the central role of multisite collaboration through shared data collection and data pooling; (4) study of time-based and interactive models of hallucination; and (5) the need to increase the accessibility and availability of "real-life" interventions for people with persisting and distressing hallucinations. Prior to the ICHR meeting, a public conference was held, titled Hearing Voices and Hallucinations: Research Practice and Recovery, with a format deliberately designed to encourage dialogue between people who experience hallucinations, scientists and practitioners. Our discussions raised a number of issues which included: the frequent neglect of positive aspects of voice hearing; the potentially therapeutic and transformative aspects of exploring meaning associated with voice content; and advantages of integrating cognitive models with subjective experience. A particular topic of discussion was the current lack of access to nonpharmacological interventions for hallucinations, with there being wide agreement on the need to improve the availability of alternative interventions.The next 2 days comprised a meeting of the working groups to review their main findings, consider recent trends, and solicit new collaborations. The working
“…Such barriers are not about the lack of knowledge, but the lack of use of existing knowledge, given that practice guidelines (eg, cognitive behavioral therapy for psychosis, and family interventions) are rarely offered systematically in clinical practice. 12,13 Difficulties include the transfer of knowledge gained under rigorous experimental conditions to clinical settings, which are often under-resourced and under pressure to provide services to clients with varied capacity and multiple comorbidities. Discussions considered the value of stepped-care models for hallucinations that provide low-intensity, low-cost, and highly accessible treatments, suitable for use by different practitioners and enhanced collaborative efforts amongst "voices clinics" to develop, test, and make widely available educational materials and resources for use across internationally varied mental health service systems.…”
a public conference in which research findings were considered in relation to subjective experience and practice, 9 multidisciplinary working groups examined key current issues in progressing the conceptualization and research of hallucinations. Work group topics included: multicenter validation of the transdiagnostic and multimodal Questionnaire for Psychotic Experiences; development of an improved outcome measure for psychological therapies; the relationship between inhibition and hallucinations across multiple levels of explanation; hallucinations in relation to sleep phenomena; emotion and hallucinations; multiple interactions between the experience of self and hallucinations; interactions between language, auditory and memory networks; resting state networks including the default mode; and analyses arising from functional magnetic resonance imaging (fMRI) data-sharing. Major themes in hallucinations research identified during the meeting included (1) progression beyond the auditory verbal modality in schizophrenia to consider hallucinations across modalities and different populations; (2) development of new measures; (3) the central role of multisite collaboration through shared data collection and data pooling; (4) study of time-based and interactive models of hallucination; and (5) the need to increase the accessibility and availability of "real-life" interventions for people with persisting and distressing hallucinations. Prior to the ICHR meeting, a public conference was held, titled Hearing Voices and Hallucinations: Research Practice and Recovery, with a format deliberately designed to encourage dialogue between people who experience hallucinations, scientists and practitioners. Our discussions raised a number of issues which included: the frequent neglect of positive aspects of voice hearing; the potentially therapeutic and transformative aspects of exploring meaning associated with voice content; and advantages of integrating cognitive models with subjective experience. A particular topic of discussion was the current lack of access to nonpharmacological interventions for hallucinations, with there being wide agreement on the need to improve the availability of alternative interventions.The next 2 days comprised a meeting of the working groups to review their main findings, consider recent trends, and solicit new collaborations. The working
“…The median incidence of schizophrenia in general population is ~1%, with 15.2 per 100,000 persons affected 11,12. This disorder affects both genders equally, despite being prone to occur earlier in men, and the effects can be long term and pervasive, with relapse being common.…”
Section: Resultsmentioning
confidence: 99%
“…This disorder affects both genders equally, despite being prone to occur earlier in men, and the effects can be long term and pervasive, with relapse being common. Although some variation by race or ethnicity has been reported, no racial differences in the prevalence of schizophrenia have been positively identified 12,13. The first episode of psychosis usually occurs in late adolescence or early adulthood, but it is frequently preceded by a prodromal phase or a so-called at-risk mental state 4,13…”
IntroductionSchizophrenia is a chronic and debilitating mental disorder that affects the patientâs and their familyâs quality of life, as well as financial costs and health care settings. Despite the variety of available antipsychotics, optimal treatment outcomes are not always achieved. Novel drugs, such as iloperidone, can provide more effective, tolerable and safer strategies.AimTo review the evidence for the clinical impact of iloperidone on the treatment of patients with schizophrenia.Evidence reviewClinical trials, observational studies and meta-analyses reached a common consensus that iloperidone is as effective as haloperidol, risperidone and ziprasidone in reducing schizophrenia symptoms. Similar amounts of adverse events and discontinuations were observed with iloperidone compared to placebo and active treatments. Common adverse events are mild and include dizziness, hypotension, dry mouth and weight gain. Iloperidone can induce extension of QTc interval, and clinicians should be aware of its contraindications. In long-term trials, iloperidone also showed promising safety and tolerability profiles. The low propensity to cause akathisia, extrapyramidal symptoms (EPS), increased prolactin levels or changes to metabolic laboratory parameters support its use in practice. Results showed that iloperidone prevents relapse in stabilized patients, with a time to relapse superior to placebo and similar to haloperidol. Patients using a prior antipsychotic (eg, risperidone and aripiprazole) can easily switch to iloperidone with no serious impact on safety or efficacy. However, the acquisition costs of iloperidone may hamper its use. Further evidence comparing iloperidone with other antipsychotics, and pharmacoeconomic studies would be welcome.Place in therapyConsidering just the clinical profile of iloperidone, it represents a promising drug for treating schizophrenia, particularly in patients who are intolerant to previous antipsychotics, as well as being suitable as first-line therapy. Cost-effectiveness comparisons are needed to justify its use in clinical practice.
“…Family intervention requires a trained member of staff to meet with family members face to face on a regular basis and has shown to be effective in reducing relapse rates for people with mental health problems [17,18], and improving relative's wellbeing [19]. However, delivering family intervention through health and social care services can be challenging due to: 1) practical difficulties gathering all family members in one room during working hours due to work and family commitments; 2) costly nature of face to face model; 3) lack of resources in services [20]. The rates of implementation for family intervention in the UK varies from 0% to 53% [20], in Western Europe is up to 15% and only about 10% of families receive family intervention in the United States [21].…”
Section: Introductionmentioning
confidence: 99%
“…However, delivering family intervention through health and social care services can be challenging due to: 1) practical difficulties gathering all family members in one room during working hours due to work and family commitments; 2) costly nature of face to face model; 3) lack of resources in services [20]. The rates of implementation for family intervention in the UK varies from 0% to 53% [20], in Western Europe is up to 15% and only about 10% of families receive family intervention in the United States [21].…”
Background: Relatives of people experiencing bipolar mood episodes or psychosis, face a multitude of challenges (e.g. social isolation, limited coping strategies, issues with maintaining relationships). Despite this, there is limited informational and emotional support for people who find themselves in supporting or caring roles. Digital technologies provide us with an opportunity to offer accessible tools, which can be used flexibly to provide evidence-based information and support, allowing relatives to build their understanding of mental health problems and learn from others who have similar experiences. However, in order to design tools that are useful to relatives, we first need to understand their needs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citationsâcitations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.